Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

YORK, Maine--(BUSINESS WIRE)--Williams Realty Partners ranked #1 in Maine by sales volume and #2 by sides among large teams in the 2026 RealTrends Verified rankings....

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health today announced advancements in how it helps streamline clinical review and create a simpler, faster, and more connected experience for care providers and members through Health OS. Health OS is Elevance Health’s secure data platform designed to connect health information across electronic health records (EHRs), labs, and health information exchanges, helping support more informed and timely clinical decisions while reducing administrative burden f...

CARLSBAD, Calif.--(BUSINESS WIRE)--Rapalogix Health, a biotechnology company advancing a science-first approach to cellular longevity and skin health, today announced the closing of a $20 million Series A financing co-led by GordonMD Global Investments® LP (“GordonMD”) — the Beverly Hills-based physician-led biopharma investment firm — and Woodline Partners. The round reflects GordonMD’s conviction that mechanism-driven platforms in dermatology represent a compelling and underserved frontier in...

PHILADELPHIA--(BUSINESS WIRE)--Enigma Networks®, the pioneer of Zero Trust for Internal Networks (ZTNX), today announced that Clutch Health has selected Enigma AI™ to strengthen continuous security monitoring, automate security operations, and streamline compliance reporting across its AI-powered patient engagement and loyalty platform. The selection comes as threat actors increasingly weaponize AI to accelerate attacks – from automated vulnerability discovery to highly targeted impersonation a...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

PARÍS--(BUSINESS WIRE)--One Biosciences, empresa pionera en perfiles tumorales unicelulares de grado clínico que combina biotecnología e inteligencia computacional, ha anunciado hoy que ha recibido financiación a través de una subvención BOOST del Paris-Saclay Cancer Cluster (PSCC) para desarrollar el primer ensayo unicelular destinado a terapias oncológicas basadas en conjugados anticuerpo-fármaco (ADC). El rápido crecimiento de los ADC hace cada vez más necesarias estrategias de biomarcadores...

PARIJS--(BUSINESS WIRE)--One Biosciences, een techbio-bedrijf dat baanbrekend werk verricht op het gebied van klinisch toepasbaar single-cell tumorprofilering, heeft vandaag financiële steun aangekondigd via een BOOST-subsidie van het Paris-Saclay Cancer Cluster (PSCC) voor de ontwikkeling van de eerste single-cell assay voor antilichaam-geneesmiddelconjugaten (ADC)-therapieën in de oncologie. De snelle groei van ADC's leidt tot een toenemende vraag naar geavanceerdere biomarkerstrategieën. Doo...

PARIS--(BUSINESS WIRE)--One Biosciences, ein Techbio-Unternehmen, das Pionierarbeit im Bereich der klinischen Einzelzell-Tumorprofilierung leistet, gab heute bekannt, dass es im Rahmen eines BOOST-Zuschusses des Paris-Saclay Cancer Cluster (PSCC) finanzielle Unterstützung für die Entwicklung des ersten Einzelzell-Assays für Antikörper-Wirkstoff-Konjugate (ADC) in der Onkologie erhält. Das rasante Wachstum im Bereich der ADCs treibt die Nachfrage nach ausgefeilteren Biomarker-Strategien voran. D...